Skye Bioscience Files Definitive Proxy Statement
Ticker: SKYE · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1516551
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
Skye Bio proxy filed - shareholders vote soon.
AI Summary
Skye Bioscience, Inc. filed its definitive proxy statement on April 25, 2025, for its annual meeting. The company, formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc., is incorporated in Nevada and operates in the pharmaceutical preparations sector. The filing details information related to the solicitation of proxies for the meeting, which is a standard corporate governance requirement.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including any proposals to be voted on, and provides information about the company's leadership and governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing, not indicating any immediate financial or operational risks.
Key Players & Entities
- Skye Bioscience, Inc. (company) — Registrant
- Emerald Bioscience, Inc. (company) — Former company name
- Nemus Bioscience, Inc. (company) — Former company name
- 20250425 (date) — Filing date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information regarding the solicitation of proxies for the company's annual meeting.
When was this filing made?
This filing was made on April 25, 2025.
What is the company's primary business sector?
The company's primary business sector is Pharmaceutical Preparations, with SIC code 2834.
Has Skye Bioscience, Inc. operated under different names previously?
Yes, Skye Bioscience, Inc. was formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc.
Where is Skye Bioscience, Inc. incorporated?
Skye Bioscience, Inc. is incorporated in Nevada (NV).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Skye Bioscience, Inc. (SKYE).